Syncoms
Work Here?
Overview
About Syncoms
Simplify's Rating
Why Syncoms is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
United Kingdom
Founded
1982
Get referred to Syncoms
See people who can refer or advise you
Simplify's Take
What believers are saying
- FY26 total income climbed to ₹5,205.11 crore, driven by pharmaceuticals.
- June 2026 quarter PAT jumped 57.8% to ₹24.85 crore.
- May 2026's ₹57.26 crore Mumbai property purchase expands corporate footprint and capital flexibility.
What critics are saying
- January 2026 GST authorities issued a ₹1.42 crore demand for alleged ineligible ITC.
- Q1 FY27 revenue grew only 7.38%, signaling weak top-line momentum.
- Any future GMP, GST, or pricing shock can crush margins and trigger delisting fears.
What makes Syncoms unique
- Syncom Formulations pairs WHO-GMP certification with ISO 9001:2015 quality controls.
- FY26 consolidated net profit rose 55.5% to ₹764.38 crore, showing scale efficiency.
- The company markets an ethical, prescription-led pharmaceutical model across India.
Help us improve and share your feedback! Did you find this helpful?
Syncoms is Hiring for 10 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →
About Syncoms
Simplify's Rating
Why Syncoms is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
United Kingdom
Founded
1982
Syncoms is Hiring for 10 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →